MNG1265
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.320
- PANCREAS_BETA_CELLS+0.292
- OXIDATIVE_PHOSPHORYLATION+0.289
- KRAS_SIGNALING_DN+0.285
- MYOGENESIS+0.247
- MYC_TARGETS_V2+0.229
- UV_RESPONSE_UP+0.218
- P53_PATHWAY+0.210
- TNFA_SIGNALING_VIA_NFKB+0.203
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.176
Top 10 suppressed
- PROTEIN_SECRETION-0.459
- G2M_CHECKPOINT-0.417
- MITOTIC_SPINDLE-0.398
- E2F_TARGETS-0.390
- UV_RESPONSE_DN-0.384
- INTERFERON_ALPHA_RESPONSE-0.357
- ALLOGRAFT_REJECTION-0.328
- INTERFERON_GAMMA_RESPONSE-0.300
- TGF_BETA_SIGNALING-0.297
- NOTCH_SIGNALING-0.295
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A8HY-01A-11R-A36F-07 | — | — | 0.852 |
| 2 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.834 |
| 3 | SRR1318372 | GTEX | — | 0.819 |
| 4 | TCGA-B6-A0I5-01A-11R-A034-07 | — | B | 0.815 |
| 5 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.809 |
| 6 | 84f39507-9883-4bab-98f9-8bd72d2aee7b | — | — | 0.806 |
| 7 | TCGA-AC-A3TM-01A-11R-A22K-07 | — | B | 0.798 |
| 8 | SRR1459804 | GTEX | — | 0.791 |
| 9 | SRR1418992 | GTEX | — | 0.789 |
| 10 | TCGA-GU-A767-01A-11R-A32O-07 | — | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.292 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.289 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.285 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.247 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.229 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.218 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.203 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.176 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.168 | Inavolisib | — uncovered |
| HYPOXIA | 0.164 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.146 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.142 | Inavolisib | — uncovered |
| COAGULATION | 0.114 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.108 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.085 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.062 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.021 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.014 | Inavolisib | — uncovered |